拉米夫定联合干扰素-α2b治疗慢性乙型肝炎疗效观察

A COMPARATIVE TRIAL OF LAMIVUDINE VS. INTERFERON-α 2b VS. A COMBINATION IN THE TREATMENT OF CHRONIC HEPATITIS B

目的 :研究比较拉米夫定 (LAM)和干扰素 (IFN -α2b)联合治疗和各自单一疗法的疗效和安全性。方法 :10 2例慢性乙型肝炎 (CHB)患者随机分组分别接受 :A)LAM ;B)IFN -α2b ;C)LAM加IFN -α2b联合治疗。结果 :治疗结束时 ,血清丙氨酸转氨酶 (ALT)复常率在A、B、C组分别为 76 .5 % (2 6 / 34)、73 .5 % (2 5 / 34)、79.4% (2 7/ 34) ;HBVDNA阴转率分别为 88.2 % (30 / 34)、41.18% (14/ 34)和 91.18% (31/ 34)。结论 :采用LAM或IFN -α2b治疗CHB均有较好的效果 。

Objective:To observe the efficacy and safety of LAM vs.1FN-α2b vs.LAM combined with 1FN-α 2b in the treatment of chronic hepatitis B.Methods:102 patients with chronic hepatitis B were divided into group A?B and C:34 patients for LAM group,34 patients for 1FN-α 2b,and 34 patients for LAM combining with 1FN-α 2b.Results:At the end of treamtent,ALT recovery rates of LAM,1FN-α 2b and LAM plus 1FN-α 2b were 76.5%(26/34),73.5%(25/34)and 79.4%(27/34),respectively.At the end of the study,HBV-DNA tarning-negative rate of LAM,1FN-α 2b and LAm plus 1FN-α 2b were 88.2%(30/34),41.2%(14/34)and 91.2%(31/34),respecively.Conclusions:The LAM or 1FN-α 2b is efficient to treat patients with choronic hepatitis B,but combining LAM with 1FN-α 2b had no cooperated effects.